Human chorionic gonadotropin (hCG) is a glycoprotein hormone, secreted by the syncytiotrophoblast cells of the fertilized ovum, that enters the maternal circulation at the time of endometrial implantation. It is composed of two nonidentical subunits; a and 1, with molecular weights of 14 kD and 23 kD, respectively. Its a subunit is identical in primary structure to its glycoprotein homologs, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Human chorionic gonadotropin binds to the same receptor as hLH and displays the same biological response, namely, to stimulate the declining function of the corpus luteum to produce progestins and estrogen late in the menstrual cycle. The differences in the structures of hCG and hLH have been exploited to develop antibodies that can measure hCG specifically in the presence of hLH.
Introduction
Human chorionic gonadotropin (hCG) is a glycoprotein hormone that is secreted by the syncytiotrophoblast and appears to enter the maternal circulation at the time of endometrial implantation of the fertilized ovum (1) . Its principal known role is to act at the ovarian corpus luteum to stimulate further the secretion of pro- gestins in support of the growth of the endometrium. Its level in blood and in urine rises rapidly to reach a maximum approximately 12 weeks after the onset of the last menstrual period; thereafter, it slowly declines until the fetus and placenta are delivered. This paper describes the development and application of an assay for this biomarker that can be used in field studies of clinically inapparent, early fetal losses. The text has been designed to provide those interested in such epidemiologic studies with a brief review of the chemistry and immunochemistry that led to a new assay for this hormone; knowledge of these features is generally essential to improvement in assay design.
It has been known for some time that hCG, in contrast to many other plasma proteins, is excreted in the urine at a concentration that is approximately equal to that in blood. The studies by Marshall et al. (2) showed this to be the case for individuals throughout the first trimester, and more recent studies have documented that the same relationship appears to exist even when minute quantities of hCG are circulating in blood (3) . Thus, urine specimens have always been a ready source for both assay and purification of this hormone. However, it is likely that urine specimens also contain partially degraded hormone fragments and measurement of a serum specimen has sometimes been preferred for diagnostic interpretation.
Biological assays for hCG were first developed by Aschheim and Zondek in the late 1920s (the A-Z test) as a method to detect pregnancy several weeks after the first missed menstrual period (4) . In the 1960s immunologic assays for hCG began to replace the more cumbersome bioassays (5, 6) . These also had the feature of increased sensitivity and reproducibility, leading to earlier diagnoses of pregnancy (7) . However, polyclonal (usually rabbit) antibodies raised against hCG always cross-reacted to some extent with the human luteinizing hormone (hLH) in the maternal circulation or with this hormone's components in urine. This is due to the considerable degree of homology between hCG and hLH. Thus, sensitivity of these assays for the early detection of pregnancy was limited by the inevitable presence of hLH immunoreactivity in maternal serum and also by either the intact hLH hormone or its fragments in urine.
In the early 1970s the relationship of all the homologous glycoprotein hormones became apparent with the discovery that each was composed of a single ao subunit and a single 13 subunit (8) . While the amino acid sequences of the a subunits of hLH and hCG were shown to be identical, there were minor differences in the structures of the 13 subunits as illustrated in the next section (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Vaitukaitis, Braunstein, and Ross found that occasionally, a rabbit, when immunized with the purified 1 subunit of hCG, made antibodies that were predominantly directed against this hormone and had limited cross-reactivity with hLH (20) . This led to the development of radioimmunoassays that could routinely detect 1 ng/mL of hCG in serum in the presence of circulating hLH. Radioimmunoassays with urine specimens were more complex because of interfering substances and the presence ofdegradation products. Many manufacturers of diagnostic kits took advantage of this assay methodology, however, and developed home testing kits for hCG in urine specimens that could detect pregnancy with moderate reliability (21) during the first 9 days after the first missed menstrual period.
Two developments opened the way for new hCG assays with enhanced sensitivity and specificity. One was the production of monoclonal antibodies against the hCG-1 subunit so that urine could be extracted efficiently by immunoaffinity adsorption. The second development was the finding that preparations of the unique 13-COOH-terminal peptide region of hCG could be employed as immunogens to make high-affinity polyclonal antibodies (22) . These are summarlzed in the following section.
The Chemistry and Immunochemistry of hCG: Similarity to hLH
Structural Considerations
The amino acid sequences of the glycoprotein hormones thyroid-stimulating hormone (TSH), folliclestimulating hormone (FSH), luteinizing hormone (LH), and chorionic gonadotropin (CG), all closely resemble each other and probably evolved from a common ancestral gene (17, 23) . Each is composed of two nonidentical subunits, designated a and 1. In the human there is only one gene for the a subunit (9) , so all of the hormones have the identical a subunit amino acid sequence, although carbohydrate differences exist (15, 17) . Hence, the structures of the 13 subunits are responsible for the different target organ specificities, and these have been shown to induce different conformational alterations when combined with their complementary a subunits (24) (25) (26) .
hLH and hCG act at the same receptor. hLH is secreted by the pituitary in a cyclic fashion during the female reproductive years, with a pulsatile surge in blood level just preceding ovulation, while hCG is the chemical message secreted by the fertilized ovum for the purpose of rescue of the corpus luteum from its declining phase, just prior to menstruation. This latter action serves to sustain a favorable endometrial environment for the implanted, fertilized ovum. hCG and hLH have very similar receptors specifying 13 subunits whose structural similarities have been preserved during evolution. The amino acid sequences of these 13 subunits, that have been derived from both protein chemical and genetic analyses (9, 11, 27) , are shown in Figure  1 . The high degree of homology for the first 113 amino acids, especially the alignment of the 12 half-cystine residues, reflects their nearly identical receptor-specifying structures. The pairing of the disulfide bridges is still not definitively proven, although two bonds appear firmly established for each subunit (17) .
The location and structures of the carbohydrate portions of hCG have been defined (Fig. 2) . The carbohydrate structures of hLH differ from those of hCG in that hLH contains a significant amount of sulfate-terminating sugar moieties as compared to the terminal sialicacid groups present in hCG (28, 29) . The carbohydrate heterogeneity of the hCG-1-COOH-terminal region is also of interest (30) , although this area of the molecule is probably more related to the prolonged circulating half-life of hCG, as compared to hLH, and not to hormone action at the receptor.
The studies by Fiddes et al. (31) suggest that an evolutionary accident occurred at the terminator codon for the 13 subunit of hCG, permitting the addition of approximately 30 amino acids to that structure, which are not present in hLH 13. This so-called 13-COOH-terminal peptide region (13-CTP) of hCG thus provides a unique epitope by which immunochemical recognition of hCG can be achieved with absolute specificity, i.e., the 13-CTP structure does not exist in hLH.
Immunochemical Considerations
Our group and many others have raised preparations of antibodies that recognize hCG and hLH to varyng degrees (32) . Of particular interest with regard to the topic discussed here are those antibodies which exhibit a high degree of selectivity for hCG, i.e., have very low reactivity with hLH. The following discussion primarily outlines results from our own research group, but the reader will also be referred to other studies that have yielded comparable results. Figure 3 depicts the a and 1 subunits of hCG. In this figure we have defined four regions, shown by the cross- Figure 1 . The following is a brief description of each of the four regions shown in Figure 3 . Region I consists of the ,-CTP of hCG. This has been isolated, coupled to carrier proteins for immunization, and shown to give rise to rabbit antibodies that are both sensitive and specific for this structure (22) . While (22, 34) . These antibodies are absolutely specific for hCG, since they are directed to a structure absent in hLH (34) . Interestingly, this region appears to be equally reactive in the native hormone, in the free subunit, and in the reduced and alkylated , subunit, suggesting that it is a structure that is loosely arranged at the surface of the hornone molecule and that the antibody combining sites recognize elements of primary structure. Chen, Matsuura, and colleagues have studied this phenomenon extensively and suggest that most of the antibodies bind to the last 15 COOH-terminal residues (35, 36 (20) . Other monoclonal antibodies listed in the figure as recognizing some elements of this general region have been defined by virtue of their ability to compete with each other for binding (32) . In addition, they all have the characteristics of binding relatively well to the I subunit, as well as to intact hCG, and each requires that the P subunit be folded in its native conformation for antibody binding.
Region III first became apparent to us when we had the opportunity to study some human autoantibodies to hCG and discovered that they reacted only with the intact hormone, exhibiting virtually no reactivity for either the isolated a or P subunits (39) . This was a distinct contrast to the antibodies of region II. Subsequently, we have discovered several monoclonal antibodies (B107 and B109), which were raised against hCG and exhibit similar properties of recognizing only the intact hormone. These also compete for reactivity at the same site as the human antiserum. Monoclonal antibody B101 has been assigned to this site, because it also competes for binding with some of the antibodies shown there (40) .
Region IV represents an epitope that is not readily reactive in native hCG but is present on the free , subunit and also on forms of the degraded hCG-,B subunit that are excreted in human urine. For this reason we suspect that it is covered in the native hormone by the a subunit and have located it as shown in Figure 3 . This is the region that has been most recently identified, and it affords the opportunity to distinguish between degraded hCG-,B subunit fragments and the intact hormone. We have determined the complete structure of the degraded 3-core fragment and have developed monoclonal antibodies that bind to region IV (41, 42) .
Taken together, these results indicate that it is possible to define four separate regions in hCG that can give rise to antibodies which may be employed in assays that will have a selectivity for hCG over hLH. Each of these regions presumably reflects a structural change resulting from amino acid differences shown in Figure  1 Figure 3 . In an early study it was found that one such assay exhibited an affinity far beyond that expected on the basis of individual antibodies. A mathematical model was developed (45, 46) 
Development of a New Assay for hCG
Given access to the immunochemical reagents just described, it became possible to devise better assays for hCG. We chose urine specimens for measurement because they were easily collected in field studies; saving the first morning voided specimen seemed much less cumbersome than attempting to obtain a 24-hr collection (47) . If this was to be the design, we next required an antibody to extract (i.e., concentrate) the hCG from urine by immunoaffinity adsorption. Monoclonal antibody B101 was our first ,3-specific antibody that became available, so we chose it as the capture antibody. B101 was coupled to Sepharose beads so that hCG could be bound to the immobilized antibody in a suspension of urine and then removed by centrifugation to form a pellet. This pellet, with the extracted hCG bound to the antibody, could then be washed and recentrifuged several times to remove any nonspecific, interfering substances, or proteolytic enzymes. Since antibodies to the 3-CTP region were absolutely specific for hCG, we elected to purify the rabbit IgG to that region (R525) and radiolabeled it with 125I as the measuring antibody. In other words, when this measuring antibody was incubated with the washed pellet, obtained from a Sepharose-B101-hCG suspension, the higher level of radioactivity bound to the solid phase, the greater the quantity of hCG attached to the capture antibody. The scheme for this immunoradiometric assay (IRMA) is shown in Figure 6A , and a standard curve for such an assay is illustrated in Figure 6B . It can be seen in Figure  6B that the hLH preparation (,ug/mL) reacts less than one part in 10,000 with hCG (ng/mL). We do not believe that this is cross-reactivity between the two, rather it represents the minute quantities of hCG that have been reported in human pituitary preparations (48-51) copurified with hLH. It can be seen from Figure 6B that this assay design permitted hCG detection at concentrations approaching 0.01 ng/mL, which was 50 to 100 times more sensitive than any other existing assay methodology.
Next we needed an indication that these low urinary concentrations actually reflected blood levels of the hormone (Fig. 7A ) and also to apply the assay to a variety of normal individuals (Fig. 7B) . Indeed, the decline of new, sensitive assay for hCG in urine specimens, but its applicability as a biomarker for early fetal loss in epidemiologic studies required evaluation. To demonstrate the applicability of hCG as a biomarker, a relatively small trial was conducted to ascertain whether the design of the study was feasible and whether new assays for hCG in urine, with enhanced sensitivity, would yield new data. Specimens were also analyzed by the method employed by an earlier investigator (53) .
The field studies enrolled women as paid volunteers. Each woman collected approximately 1 ounce of urine each morning and stored the containers frozen until they were picked up for assay. Details of the study design have been described elsewhere (47) . To date, we have completed three studies testing the utility of these assays. In the first, 30 women collected daily urine specimens from the time they stopped contraception until they became pregnant, or for six months ifno pregnancy occurred (47) . This study not only showed the feasibility of the epidemiologic design, but it also permitted the detection of several cycles with early fetal loss that would not have been detected by any other available methodologies. This preliminary study is the basis for a larger study currently in progress, which will more accurately define the incidence of such clinically unrecognized early fetal loss.
A second study group was composed of women who had undergone tubal ligation; no patterns suggestive of pregnancy have been seen so far. In the third group, women who were using intrauterine devices as a means of contraception were evaluated to determine whether this contraceptive technique prevented implantation of the fertilized ovum. Urinary hCG was -detected in only 1 of 107 menstrual cycles in this study (54) Three consecutive menstrual cycles ofone individual are illustrated in which urine specimens were collected daily. During the first cycle no conception occurred. All hCG values were less than 0.01 ng/mL. During the second cycle, 3 weeks after the onset ofthe prior menstrual period, urinary hCG rose for 6 days to 0.38 ng/mL. Human chorionic gonadotropin steadily declined over the next 6 days, returning to undetectable levels. With the decline of hCG came the onset of menses, 27 days after the onset of the previous menses. This individual was unaware of her pregnancy or the episode of early fetal loss. However, the finding of 11 consecutive elevations of urinary hCG above the normal background for this individual, in a pattern of rise and then fall, leave little doubt that a loss has occurred. Three weeks after the apparent fetal loss, this woman again exhibited a rising level of urinary hCG. This time she remained pregnant and delivered a normnal, full-term infant.
One additional point should be added concerning the advantage of an immunoradiometric assay. When a conventional radioimmunoassay is perfonned on a urine specimen, contaminating proteolytic enzymes in the urine may degrade the radiolabeled tracer during its incubation. This proteolytic artifact may lead to falsely elevated measurements of hCG. In addition, other interfering urinary substances may add to background baseline variations and decrease the signal-to-noise ratio for detection of pregnancy. In the immunoradiometric assay, the radioactive tracer is introduced after proteases and interfering substances have been washed away. For example, the SB-6 radioimmunoassay in urine displays a poor signal-to-noise ratio with a wide variation between 1 to 10 ngfmL (47) . This contrasts with the data from the immunoradiometric assay performed on the same specimens which display greater sensitivity for hCG without the widely fluctuating baseline (47) . These factors may have contributed to the differing results (8-57%) obtained in prior studies of early fetal loss (56) (57) (58) .
Rationale for Future Assay Developments
As noted at the outset, tests for hCG have evolved over the past 5 decades from crude bioassays to highly sensitive and specific immunoassays. The hCG molecule is well-characterized and a relatively specific product of pregnancy. Its ectopic secretion by some tumors and its slight elevation in postmenopausal women (49) (50) (51) (52) do not lessen its epidemiologic value as a biomarker for pregnancy in healthy women of reproductive age. Other placental proteins that have been described as pregnancy-specific have proven to be of less utility to detect early pregnancy. Furthermore, these products are typically assayed in blood, and their fate in urine is less well known (59) .
The careful description of early pregnancy loss requires not only a reliable assay but also frequent mea-surement. The collection of daily urine specimens from women attempting pregnancy has proven to be feasible. Data from such studies show that hCG can be detected within a few days of the expected date of implantation and, on average, at least 2 days before the onset of the expected next menses. Early fetal losses are detectable with this approach, although an assay needs to be sensitive and reliable to at least 0.05 ng/mL of hCG in order to detect most of these losses clearly.
Many research groups have contributed to advances in the techniques for studying early pregnancy. Still more remains to be done if epidemiologic studies are to be carried out efficiently. The best available methods for measuring hCG are complex, time-consuming, and expensive. We suggest here some specific and feasible ways in which hCG assays might be refined.
New Monoclonal Antibodies for hCG Detection
Although urinary hCG is predominantly in its intact form, there are several forms of fragmentary hCG as well, each with distinct immunochemical properties. In order to measure the complete urinary products of hCG, new antibodies with high affinities for the various products are needed. Ideally, these should be monoclonal antibodies, in order to assure a continuous supply of well-characterized reagents. The complete detection of hCG in its various forms would maximize sensitivity and assure that unusual events such as a decrease in the secretion of one of the subunits could be described.
Nonradioactive Methods for hCG Detection
The use of radioactive iodine in immunoassays has been highly successful, but not without disadvantages. First, radiolabeled reagents must be freshly prepared and characterized every few weeks and then shipped to users. Second, the use of radioactive materials in the laboratory requires special training and surveillance. Third, there is an increasing problem with radioactive waste disposal. The application of newer technologies such as a fluorescent immunoassay would allow greater ease and flexibility of laboratory support for field studies.
Systematic Comparisons of hCG Assays
The suggestions above are aimed toward making hCG assays as accurate, rapid, and inexpensive as possible. Such improvements would greatly increase the applicability of such assays in epidemiologic studies. However, with every change in assay method, there is the problem of potential noncomparability of results among different assays. Every effort should be made to characterize the properties of new assays in a way that will allow the results of epidemiologic studies to be meaningfully compared.
Related Research Opportunities
Urinary hCG is a useful marker for detecting the fertilized ovum around the time of implantation. However, this marker cannot detect earlier loss of the ovum. Possible methods for earlier detection of pregnancy should be pursued (60) .
In the broader context of reproductive studies, there is a need for continued progress in the development of markers of ovarian function, including ovulation. As with hCG, the most useful markers for epidemiologic research are those detectable in easily collected biological specimens such as urine or saliva. The pituitary gonadotropins (hLH and hFSH) can be useful for determining the timing of ovulation (1) . The various estrogen and progesterone derivatives can be used to identify ovulation as well as to measure the follicular and luteal functions of the ovary. The same improvements that were discussed for hCG assays would be useful for assays of these hormones. There are clinical questions as well that can be addressed by studies of early fetal loss. These focus mainly on the possible contribution of unrecognized loss to infertility. Syndromes involving very early loss may be so rare as to be unimportant to epidemiologic studies of environmental hazards, but the syndromes are important nonetheless for diagnosis and treatment of infertility. All these basic questions, whether coming from the epidemiologist or the clinician, are now answerable with tools that were unavailable until recently. Work will be further enhanced when more convenient assays for hCG are available.
